Revolution Medicines reported third-quarter 2026 financial results, generating $197.6 million in net product revenue from its recently launched drug RASONQUE (daraxonrasib). The company also announced a positive CHMP opinion recommending EU approval for the pancreatic cancer treatment and received FDA Breakthrough Therapy Designation for daraxonrasib in combination with chemotherapy. Additionally, the firm disclosed new clinical collaborations and progress across its oncology pipeline.
